Market reconsiders Johnson & Johnson vaccine news

Market decides it's good enough
The headline from the JNJ vaccine trial was 66% effectiveness and only 57% in South Africa, which has a worrisome variant.
On the surface, that doesn't sound like the #1 vaccine that anyone wants to get but medical experts — including Fauci — have chimed in to say the news is better